Search for a command to run...
Medplus Health Services Ltd. shows strong revenue growth and efficiency metrics compared to its peers, but its high PE ratio indicates it may be overvalued. Companies like Cipla and Dr. Reddy's Laboratories stand out for their profitability and reasonable valuation, while Divi's Laboratories faces challenges due to poor revenue growth.
Stocks | CMP | Market Cap | P/E | ROCE (%) | Debt/Equity |
---|---|---|---|---|---|
MEDPLUS | ₹832.95 | ₹9,969.91Cr | 247.28 | 18.22% | - |
SUNPHARMA | ₹1,563.35 | ₹3,75,099.26Cr | 87.59 | 17.60% | 0.04 |
DIVISLAB | ₹6,091.05 | ₹1,61,698.50Cr | 73.20 | 16.46% | - |
CIPLA | ₹1,587.60 | ₹1,28,217.27Cr | 23.73 | 22.77% | 0.01 |
TORNTPHARM | ₹3,581.55 | ₹1,21,215.77Cr | 61.53 | 24.28% | 0.57 |
DRREDDY | ₹1,280.30 | ₹1,06,835.27Cr | 15.50 | 26.86% | 0.07 |
MANKIND | ₹2,518.95 | ₹1,03,926.59Cr | 55.18 | 28.38% | 0.02 |